Joint application:
with methotrexate at a dose of 15 mg per week or more: increases the hemolytic cytotoxicity of methotrexate (decreased renal clearance of methotrexate and methotrexate is replaced by salicylates in association with blood plasma proteins);
with anticoagulants, for example, heparin: increased risk of bleeding due to inhibition of platelet function, damage to the mucosa of the gastrointestinal tract, displacement of anticoagulants (oral) from the connection with blood plasma proteins;
with other non-steroidal anti-inflammatory drugs, as well as with high doses of salicylates (3 grams per day or more): as a result of synergistic interaction, the risk of ulcers of the stomach and duodenum and bleeding from the gastrointestinal tract increases;
with uricosuric agents, for example benzbromarone: reduces the uricosuric effect;
with digoxin: Digoxin concentration is increased due to decreased renal excretion;
with hypoglycemic drugs, for example insulin - increased hypoglycemic effect of hypoglycemic drugs due to hypoglycemic effect of acetylsalicylic acid;
with preparations of thrombolytics group: the risk of bleeding increases;
with diuretics: decreased glomerular filtration due to reduced synthesis of prostaglandins;
from systemic glucocorticosteroids, excluding hydrocortisone, used and quality of substitution treatment in case of illness Addison: when applying glucocorticosteroids reduces the concentration of salicylates in the blood by increasing the excretion of the latter;
with inhibitors of angiotensin-converting enzyme: at a dose of 3 g per day and more glomerular filtration is reduced by inhibiting the action of prostaglandins and, as a consequence, the antihypertensive effect decreases;
with valproic acid: increases the toxicity of valproic acid;
with ethanol: the risk of damaging effects on the mucous membrane of the gastrointestinal tract increases and the bleeding time increases.